MRNA - Moderna, Inc.

49.83
-3.015   -6.051%

Share volume: 8,584,817
Last Updated: 03-03-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.31%

PREVIOUS CLOSE
CHG
CHG%
$52.84
-3.02
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
13%
Profitability 0%
Dept financing 9%
Liquidity 45%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.98%
1 Month
16.51%
3 Months
95.49%
6 Months
105.23%
1 Year
64.08%
2 Year
-48.09%
Key data
Stock price
$49.83
P/E Ratio 
0.00
DAY RANGE
$48.09 - $51.86
EPS 
-$7.26
52 WEEK RANGE
$22.28 - $55.20
52 WEEK CHANGE
$41.52
MARKET CAP 
11.521 B
YIELD 
N/A
SHARES OUTSTANDING 
394.939 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-31-2025
BETA 
0.33
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$8,472,379
AVERAGE 30 VOLUME 
$10,215,732
Company detail
CEO: Stéphane Bancel
Region: US
Website: modernatx.com
Employees: 3,900
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Moderna, Inc. develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. The company has 44 development programs, which includes 26 in clinical trials across seven modalities.

Recent news